AstraZeneca likely to have COVID-19 vaccine against South African variant by 2021-end
Sarah Walters, AstraZeneca's Austria country manager said so far, indicating the existing AstraZeneca vaccine was less effective against the more infectious variant first documented in South Africa were "too small to draw final conclusions"
Australia reports first fatality from blood clots 'likely' linked to AstraZeneca COVID-19 vaccine
Australia's Vaccine Safety Investigation Group (VSIG), which held a late meetig on Friday, concluded the New South Wales woman's death was likely linked to the vaccination, the Therapeutic Goods Administration said in a statement
AstraZeneca Pharma India Ltd - 506820 - Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0330 Name of the Signatory :- PRATAP RUDRADesignation :- Company Secretary and Compliance Officer ASTRAZENECA PHARMA INDIA LTD. - 506820 - Certificate Under Regulation 40(10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
As required under Regulation 40(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we furnish herewith a Certificate issued by the Practicing Company Secretary with regard to transfer of securities effected during the period October 1, 2020 to March 31, 2021. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Certificate Under Regulation 40(10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
As required under Regulation 40(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we furnish herewith a Certificate issued by the Practicing Company Secretary with regard to transfer of securities effected during the period October 1, 2020 to March 31, 2021.
In world first, Denmark ditches AstraZeneca's coronavirus vaccine
Many countries in Europe and elsewhere have resumed administering the shot, with some restricting its use to certain age groups, mostly those aged above 50 or above 60.
COVID-19 Vaccine Update: Germany to give different second jab to AstraZeneca recipients under 60
Germany announced on March 30 that it would no longer offer the two-dose AstraZeneca vaccine to people aged under 60 due to concerns over a possible link to rare cases of blood clots.
Covid-19 vaccines reduce chances of severe infection, mortality: ICMR
COVID-19 vaccines reduce the chances of developing severe infection and mortality, ICMRChief Balram Bhargava said on Tuesday. Responding to a question about people contracting the coronavirus infection even after taking both doses of COVID vaccine, he said these are "disease-modifying" vaccines and there is an 85 percent reduction in hospitalisation after vaccination which is well established internationally. "These vaccines are disease-modifying. After two doses are administered, the antibodies develop.The COVID-19 vaccines reduce the chances of developing severe infection and death due to the disease," the ICMR Director General said. The Indian Council of Medical Research (ICMR) is the country's apex health research body. Currently, two vaccines -- Covaxin by Bharat Biotech and Oxford-AstraZeneca's Covishield manufactured by Serum Institute of India (SII) -- are being used for inoculation in India. India's drug regulator has also granted permission for the restricted emergency u
AstraZeneca says diabetes drug Farxiga fails in trial to treat covid patients
The British drugmaker said Farxiga did not achieve statistical significance in cutting the risk of the disease worsening and death in such patients.
Covid-19 vaccine shortages hit 60 poor countries in 'shocking imbalance'
Shortage stems mostly from India's decision to stop exporting vaccines from its Serum Institute factory, which produces the overwhelming majority of the AstraZeneca doses.